{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:03:44Z","timestamp":1777521824747,"version":"3.51.4"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PLANET22I0"],"award-info":[{"award-number":["PLANET22I0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["PLANET19G0"],"award-info":[{"award-number":["PLANET19G0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["FISCHE20A0-KB"],"award-info":[{"award-number":["FISCHE20A0-KB"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jcf.2023.10.014","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T02:27:00Z","timestamp":1699583220000},"page":"8-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A birth cohort approach to understanding cystic fibrosis lung infections"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7179-6400","authenticated-orcid":false,"given":"Anthony J.","family":"Fischer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Planet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2023.10.014_bib0001","unstructured":"Cystic Fibrosis Foundation. 2020 Patient Registry Annual Data Report from Years 2014, 2015, 2017, 2019, and 2020. 2021. Bethesda, Maryland. Images received by email on January 23, 2023 and available online < https:\/\/www.cff.org\/sites\/default\/files\/2021-11\/2020%20Annual%20Data%20Report.pdf>Date Accessed: September 25, 2023."},{"key":"10.1016\/j.jcf.2023.10.014_bib0002","series-title":"UK cystic fibrosis registry 2021 annual data report","year":"2022"},{"key":"10.1016\/j.jcf.2023.10.014_bib0003","unstructured":"Mukoviszedose eintragener Verein. German Cystic Fibrosis Registry Annual Report 2021. 2022. < https:\/\/www.muko.info\/fileadmin\/user_upload\/was_wir_tun\/register\/berichtsbaende\/annual_report_2021.pdf>Date Accessed: September 25, 2023."},{"key":"10.1016\/j.jcf.2023.10.014_bib0004","unstructured":"Cystic Fibrosis Canada. The Canadian Cystic Fibrosis Registry 2021 Annual Data Report. 2022. < https:\/\/www.cysticfibrosis.ca\/uploads\/2021-Annual-Data-Report-WEB-AODA.pdf>Date Accessed: September 25, 2023."},{"key":"10.1016\/j.jcf.2023.10.014_bib0005","unstructured":"Cystic Fibrosis Australia. Australian cystic fibrosis data registry, 2021. 2022. < https:\/\/cysticfibrosis.org.au\/wp-content\/uploads\/2023\/05\/2021-ACFDR-Annual-Report.pdf>Date Accessed: September 25, 2023."},{"key":"10.1016\/j.jcf.2023.10.014_bib0006","article-title":"Longitudinal bacterial prevalence in cystic fibrosis airways: fact and artifact","author":"VanDevanter","year":"2023","journal-title":"J Cyst Fibros Off J Eur Cyst Fibros Soc"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.014_bib0007","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1128\/CMR.15.2.194-222.2002","article-title":"Lung infections associated with cystic fibrosis","volume":"15","author":"Lyczak","year":"2002","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.014_bib0008","doi-asserted-by":"crossref","first-page":"6748","DOI":"10.1038\/s41598-019-42952-x","article-title":"Anaerobiosis influences virulence properties of Pseudomonas aeruginosa cystic fibrosis isolates and the interaction with Staphylococcus aureus","volume":"9","author":"Pallett","year":"2019","journal-title":"Sci Rep"},{"issue":"14","key":"10.1016\/j.jcf.2023.10.014_bib0009","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1128\/JB.00303-15","article-title":"Iron-Mediated Control of Pseudomonas aeruginosa-Staphylococcus aureus Interactions in the Cystic Fibrosis Lung","volume":"197","author":"Barnabie","year":"2015","journal-title":"J Bacteriol"},{"issue":"15","key":"10.1016\/j.jcf.2023.10.014_bib0010","doi-asserted-by":"crossref","DOI":"10.1093\/femsle\/fnx128","article-title":"The role of multispecies social interactions in shaping Pseudomonas aeruginosa pathogenicity in the cystic fibrosis lung","volume":"364","author":"O'Brien","year":"2017","journal-title":"FEMS Microbiol Lett"},{"key":"10.1016\/j.jcf.2023.10.014_bib0011","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41522-017-0035-0","article-title":"Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance","volume":"3","author":"Beaudoin","year":"2017","journal-title":"NPJ Biofilms Microbiomes"},{"issue":"14","key":"10.1016\/j.jcf.2023.10.014_bib0012","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1007\/s00253-016-7596-3","article-title":"Interactions between Pseudomonas aeruginosa and Staphylococcus aureus during co-cultivations and polymicrobial infections","volume":"100","author":"Nguyen","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"issue":"14","key":"10.1016\/j.jcf.2023.10.014_bib0013","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1128\/JB.00059-15","article-title":"Coculture of Staphylococcus aureus with Pseudomonas aeruginosa Drives S. aureus towards Fermentative Metabolism and Reduced Viability in a Cystic Fibrosis Model","volume":"197","author":"Filkins","year":"2015","journal-title":"J Bacteriol"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.014_bib0014","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.014_bib0015","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1164\/rccm.200208-855OC","article-title":"Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis","volume":"167","author":"Gibson","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.014_bib0016","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1067\/mpd.2002.121930","article-title":"Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial","volume":"140","author":"Stutman","year":"2002","journal-title":"J Pediatr"},{"issue":"14","key":"10.1016\/j.jcf.2023.10.014_bib0017","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1056\/NEJM199710023371403","article-title":"Nutritional benefits of neonatal screening for cystic fibrosis. Wisconsin cystic fibrosis neonatal screening study group","volume":"337","author":"Farrell","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.014_bib0018","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJM199901073400104","article-title":"Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic fibrosis inhaled tobramycin study group","volume":"340","author":"Ramsey","year":"1999","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.jcf.2023.10.014_bib0019","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.jcf.2023.10.014_bib0020","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.014_bib0021","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1067\/mic.2003.78","article-title":"Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission","volume":"31","author":"Saiman","year":"2003","journal-title":"Am J Infect Control"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.014_bib0022","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1086\/676882","article-title":"Infection prevention and control guideline for cystic fibrosis: 2013 update","volume":"35","author":"Saiman","year":"2014","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.014_bib0023","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jcf.2023.10.014_bib0024","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1378\/chest.110.4.889","article-title":"Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group","volume":"110","author":"McCoy","year":"1996","journal-title":"Chest"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.014_bib0025","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1067\/mpd.2001.118570","article-title":"A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities","volume":"139","author":"Quan","year":"2001","journal-title":"J Pediatr"},{"issue":"18","key":"10.1016\/j.jcf.2023.10.014_bib0026","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.jcf.2023.10.014_bib0027","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.jcf.2023.10.014_bib0028","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jcf.2023.10.014_bib0029","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1513\/AnnalsATS.201402-050AS","article-title":"Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections","volume":"11","author":"Chmiel","year":"2014","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.jcf.2023.10.014_bib0030","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47365","article-title":"Interspecies interactions induce exploratory motility in Pseudomonas aeruginosa","volume":"8","author":"Limoli","year":"2019","journal-title":"eLife"},{"issue":"2","key":"10.1016\/j.jcf.2023.10.014_bib0031","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpeds.2008.08.001","article-title":"Impact of pseudomonas and staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis","volume":"154","author":"Sagel","year":"2009","journal-title":"J Pediatr"},{"issue":"23","key":"10.1016\/j.jcf.2023.10.014_bib0032","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1001\/jama.2010.791","article-title":"Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis","volume":"303","author":"Dasenbrook","year":"2010","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jcf.2023.10.014_bib0033","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/ppul.20604","article-title":"Presence of methicillin resistant Staphylococcus aureus in respiratory cultures from cystic fibrosis patients is associated with lower lung function","volume":"42","author":"Ren","year":"2007","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.jcf.2023.10.014_bib0034","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/ppul.23217","article-title":"Risk factors for lung function decline in a large cohort of young cystic fibrosis patients","volume":"50","author":"Cogen","year":"2015","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.jcf.2023.10.014_bib0035","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1164\/rccm.202004-1322OC","article-title":"Sustained coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in cystic fibrosis","volume":"203","author":"Fischer","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.jcf.2023.10.014_bib0036","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1128\/JCM.41.9.4424-4427.2003","article-title":"Population dynamics of persistent Staphylococcus aureus isolated from the airways of cystic fibrosis patients during a 6-year prospective study","volume":"41","author":"Kahl","year":"2003","journal-title":"J Clin Microbiol"},{"issue":"5","key":"10.1016\/j.jcf.2023.10.014_bib0037","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00832-2017","article-title":"Airway microbiota across age and disease spectrum in cystic fibrosis","volume":"50","author":"Zemanick","year":"2017","journal-title":"Eur Respir J"},{"issue":"10","key":"10.1016\/j.jcf.2023.10.014_bib0038","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1513\/AnnalsATS.201702-121OC","article-title":"Association of antibiotics, airway microbiome, and inflammation in infants with cystic fibrosis","volume":"14","author":"Pittman","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"10.1016\/j.jcf.2023.10.014_bib0039","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1136\/thoraxjnl-2016-209279","article-title":"The lower airway microbiota in early cystic fibrosis lung disease: a longitudinal analysis","volume":"72","author":"Frayman","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2023.10.014_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2022.885822","article-title":"Changes in microbiome dominance are associated with declining lung function and fluctuating inflammation in people with cystic fibrosis","volume":"13","author":"Frey","year":"2022","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.jcf.2023.10.014_bib0041","doi-asserted-by":"crossref","first-page":"18593","DOI":"10.1038\/s41598-019-55028-7","article-title":"Gut microbiota in children with cystic fibrosis: a taxonomic and functional dysbiosis","volume":"9","author":"Coffey","year":"2019","journal-title":"Sci Rep"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199323016624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T04:10:19Z","timestamp":1767240619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199323016624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S1569199323016624"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.014","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A birth cohort approach to understanding cystic fibrosis lung infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2023.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}